Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: A randomized trial

Kim Brixen, Roland Chapurlat, Angela M. Cheung, Tony M. Keaveny, Thomas Fuerst, Klaus Engelke, Robert Recker, Bernard Dardzinski, Nadia Verbruggen, Shabana Ather, Elizabeth Rosenberg, Anne E. De Papp

Research output: Contribution to journalArticle

94 Scopus citations

Abstract

Context: Odanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD)in postmenopausal women with low BMD and cortical thickness in ovariectomized monkeys. Objective: The objective of the study was to examine the impact of odanacatib on the trabecular and cortical bone compartments and estimated strength at the hip and spine. Design: This was a randomized, double-blind, 2-year trial. Setting: The study was conducted at a private or institutional practice. Participants: Participants included 214 postmenopausal women with low areal BMD. Intervention: The intervention included odanacatib 50 mg or placebo weekly. Main Outcome Measures: Changes in areal BMD by dual-energy x-ray absorptiometry (primary end point, 1 year areal BMD change at lumbar spine), bone turnover markers, volumetric BMD by quantitative computed tomography (QCT), and bone strength estimated by finite element analysis were measured. Results: Year 1 lumbar spine areal BMD percent change from baseline was 3.5% greater with odanacatib than placebo (P

Original languageEnglish (US)
Pages (from-to)571-580
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number2
DOIs
StatePublished - Feb 2013

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: A randomized trial'. Together they form a unique fingerprint.

  • Cite this

    Brixen, K., Chapurlat, R., Cheung, A. M., Keaveny, T. M., Fuerst, T., Engelke, K., Recker, R., Dardzinski, B., Verbruggen, N., Ather, S., Rosenberg, E., & De Papp, A. E. (2013). Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: A randomized trial. Journal of Clinical Endocrinology and Metabolism, 98(2), 571-580. https://doi.org/10.1210/jc.2012-2972